TD Cowen analyst Josh Jennings maintains $TransMedics (TMDX.US)$ with a buy rating, and maintains the target price at $175.
According to TipRanks data, the analyst has a success rate of 54.6% and a total average return of 5.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $TransMedics (TMDX.US)$'s main analysts recently are as follows:
TransMedics' Q3 outcomes fell short of expectations, yet the management upheld its FY24 forecasts, suggesting a broad spectrum for Q4 growth. Despite a sequential dip in transplant volumes across all three organ categories, the company maintains that it has not conceded market share during Q3. The firm's position as a 'market leader in a still very underpenetrated market' remains recognized by analysts.
The firm indicated that although they anticipated a more modest upside in Q3, TransMedics' earnings miss was unexpected. Nonetheless, the company reported a substantial growth of +64% and maintained their FY24 guidance, attributing challenges to temporary factors rather than market share losses or pricing pressures regarding OCS disposables.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
TD Cowen分析師Josh Jennings維持$TransMedics (TMDX.US)$買入評級，維持目標價175美元。
根據TipRanks數據顯示，該分析師近一年總勝率為54.6%，總平均回報率為5.0%。
此外，綜合報道，$TransMedics (TMDX.US)$近期主要分析師觀點如下：
TransMedics第三季度的業績低於預期，但管理層維持了其24財年的預測，表明第四季度的增長範圍廣泛。儘管所有三個器官類別的移植量連續下降，但該公司堅持認爲在第三季度沒有讓出市場份額。該公司作爲 「在滲透率仍然很低的市場中的市場領導者」 的地位仍然得到分析師的認可。
該公司表示，儘管他們預計第三季度將出現更溫和的上漲空間，但TransMedics的盈利虧虧出乎意料。儘管如此，該公司報告實現了64％的大幅增長，並維持了24財年的預期，將挑戰歸因於臨時因素，而不是OCS一次性用品的市場份額損失或定價壓力。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
